Table 1
% CD40L+IFNg+/CD4+ T cells
*
% CD40L+TNFa+/CD4+ T cells
*
% CD40L+IL-17+/CD4+ T cells
**
Controls
14.8±4.5
18.01±6.6
0.15±0.11
BL Ustekinumab
16.6±7.4
22.9±11.1
0.18±0.13
W 24 Ustekinumab
16.7±8.4
20.4±13.2
0.19±0.19
↵
*
PMA/I stimulation;
↵
**
SEB stimulation.